Baird analyst Brian Skorney lowered the firm’s price target on Biogen (BIIB) to $255 from $300 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where they beat on both top and bottom line which were mitigated by questions on Leqembi growth.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue